Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment

The requested reference [b36aa6b67cfa58ea371dff217cbcd6291b1bd394] no longer exists in our database. It has been replaced by the current reference: [fdb7cb983959af102d3e581b85199ac60ae649dd]

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2019
This article has no abstract
Epistemonikos ID: f398e35faa8396e681ddf8a4c3571d48e653fe24
First added on: Apr 29, 2026